TN2011000370A1 - Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof - Google Patents

Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof

Info

Publication number
TN2011000370A1
TN2011000370A1 TN2011000370A TN2011000370A TN2011000370A1 TN 2011000370 A1 TN2011000370 A1 TN 2011000370A1 TN 2011000370 A TN2011000370 A TN 2011000370A TN 2011000370 A TN2011000370 A TN 2011000370A TN 2011000370 A1 TN2011000370 A1 TN 2011000370A1
Authority
TN
Tunisia
Prior art keywords
amino acid
acid ester
alkylamine
ester prodrugs
dicyanopyridine
Prior art date
Application number
TN2011000370A
Other languages
English (en)
Inventor
Alexandros Vakalopoulos
Daniel Meibom
Barbara Albrecht-Kupper
Katja Zimmermann
Joerg Keldenich
Hans-Georg Lerchen
Peter Nell
Frank Sussmeier
Ursula Krenz
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41724154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000370(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of TN2011000370A1 publication Critical patent/TN2011000370A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
TN2011000370A 2009-01-29 2011-07-27 Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof TN2011000370A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009006602A DE102009006602A1 (de) 2009-01-29 2009-01-29 Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
PCT/EP2010/000262 WO2010086101A1 (fr) 2009-01-29 2010-01-19 Dicyanopyridine à substitution alkylamino et ses promédicaments d'ester d'acide aminé

Publications (1)

Publication Number Publication Date
TN2011000370A1 true TN2011000370A1 (en) 2013-03-27

Family

ID=41724154

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000370A TN2011000370A1 (en) 2009-01-29 2011-07-27 Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof

Country Status (42)

Country Link
US (3) US8420825B2 (fr)
EP (2) EP2743270B1 (fr)
JP (2) JP5693469B2 (fr)
KR (2) KR101833188B1 (fr)
CN (2) CN102388040B (fr)
AR (1) AR075050A1 (fr)
AU (1) AU2010207786B2 (fr)
BR (1) BRPI1007308A2 (fr)
CA (2) CA2750769C (fr)
CO (1) CO6400193A2 (fr)
CR (1) CR20110407A (fr)
CU (1) CU24037B1 (fr)
CY (2) CY1115403T1 (fr)
DE (1) DE102009006602A1 (fr)
DK (2) DK2391620T3 (fr)
DO (1) DOP2011000243A (fr)
EA (1) EA019275B1 (fr)
EC (1) ECSP11011235A (fr)
ES (2) ES2473966T3 (fr)
GT (1) GT201100205A (fr)
HK (2) HK1168353A1 (fr)
HN (1) HN2011002037A (fr)
HR (2) HRP20140714T1 (fr)
HU (1) HUE032008T2 (fr)
IL (1) IL214019A0 (fr)
JO (1) JO2927B1 (fr)
LT (1) LT2743270T (fr)
MA (1) MA33000B1 (fr)
MX (1) MX2011007800A (fr)
MY (1) MY156434A (fr)
NZ (1) NZ594267A (fr)
PE (2) PE20120430A1 (fr)
PL (2) PL2743270T3 (fr)
PT (2) PT2391620E (fr)
RS (1) RS53448B (fr)
SG (1) SG172968A1 (fr)
SI (2) SI2743270T1 (fr)
TN (1) TN2011000370A1 (fr)
TW (2) TWI511968B (fr)
UA (1) UA104613C2 (fr)
UY (1) UY32393A (fr)
WO (1) WO2010086101A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004042607A1 (de) 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
WO2009143992A1 (fr) 2008-05-29 2009-12-03 Bayer Schering Pharma Aktiengesellschaft Dicyanopyridines substituées par du 2-alcoxy et leur utilisation
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
AR094180A1 (es) 2012-12-21 2015-07-15 Sanofi Sa Derivados de exendina-4
MX2016007343A (es) * 2013-12-12 2016-09-13 Bayer Pharma AG Agonistas de a1 de adenosina como medicamentos para trastornos renales.
US9318574B2 (en) 2014-06-18 2016-04-19 International Business Machines Corporation Method and structure for enabling high aspect ratio sacrificial gates
ES2744227T3 (es) * 2015-05-06 2020-02-24 Bayer Pharma AG Procedimiento para la preparación de monoclorhidrato de L-alanil-L-alaninato de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4-il]fenoxi}etilo
WO2017137528A1 (fr) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Agoniste du récepteur a1 de l'adénosine pour utilisation dans le traitement de l'état de mal épileptique
WO2018108884A1 (fr) 2016-12-16 2018-06-21 Bayer Pharma Aktiengesellschaft Formulation de comprimés pharmaceutiques
WO2018153895A1 (fr) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec un inhibiteur de l'endopeptidase neutre et/ou un antagoniste du récepteur de l'angiotensine ii
WO2018153899A1 (fr) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des stimulateurs et/ou activateurs de la guanylate cyclase soluble (sgc)
WO2018153897A1 (fr) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs des canaux hcn
WO2018153900A1 (fr) * 2017-02-22 2018-08-30 Bayer Aktiengesellschaft Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs de sglt-2
WO2018153898A1 (fr) * 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des antagonistes du récepteur des minéralocorticoïdes
WO2018219804A1 (fr) * 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Systèmes d'administration de médicaments auto-émulsifiants
WO2018219801A1 (fr) 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Extrudats à libération immédiate
WO2019180072A1 (fr) 2018-03-22 2019-09-26 Bayer Pharma Aktiengesellschaft Composition pharmaceutique parentérale consistant en du bialanate de néladénoson

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052510A (en) * 1974-12-18 1977-10-04 Sandoz, Inc. 4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity
TW299333B (fr) 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
EP0765327B1 (fr) 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo et pyrrolopyridines
DE4430638A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
JPH09132529A (ja) 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
HUP9902056A3 (en) 1996-01-17 2002-02-28 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
EP2311806A3 (fr) 1996-01-29 2011-08-10 The United States of America, Represented by the Secretary, Department of Health and Human Services Dérivés de dihydropyridine, pyridine, benzopyranone et triazoloquinazoline, leur préparation et leur utilisation en tant qu'antagonistes de récepteur d'adénosine
JPH10324687A (ja) 1997-02-19 1998-12-08 Nippon Soda Co Ltd ピロール化合物、製法および農園芸用殺菌剤
JP2002507197A (ja) * 1997-05-30 2002-03-05 ビーエーエスエフ アクチェンゲゼルシャフト 置換チオピリジン
WO1999003861A1 (fr) 1997-07-16 1999-01-28 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee, leur preparation et utilisation
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE19834047A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) * 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19947154A1 (de) * 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
EP1261327B1 (fr) * 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Modulateurs de recepteurs de l'adenosine
WO2002006237A1 (fr) * 2000-07-18 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Medicament comprenant un derive de dicyanopyridine
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
EP1341772A2 (fr) 2000-12-11 2003-09-10 E. I. du Pont de Nemours and Company Quinazolinones et pyridinylpyrimidinones pour la regulation de nuisibles invertebres
ATE318812T1 (de) * 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
DE10110438A1 (de) * 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10115922A1 (de) * 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) * 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003183254A (ja) 2001-12-20 2003-07-03 Yamanouchi Pharmaceut Co Ltd ２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩
WO2003091246A1 (fr) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Derives de pyrrole utilises en tant qu'inhibiteurs de erk2 et leurs utilisations
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004013149A1 (fr) * 2002-08-02 2004-02-12 Dow Global Technologies Inc. Complexes de metaux du groupe 4 contenant des derives indenyles tricycliques 4-aryle-substitues
EP1388342A1 (fr) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Dérivés de cycloalkenylamine condensé avec un hététoaryle et acylé et leur utilisation comme produits pharmaceutiques
US7186716B2 (en) * 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
MXPA05006367A (es) 2002-12-12 2005-08-29 Pharmacia Corp Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
TWI270549B (en) * 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1667683A4 (fr) * 2003-09-23 2009-04-29 Merck & Co Inc Inhibiteurs des canaux potassiques a la quinoleine
US7338951B2 (en) * 2003-11-10 2008-03-04 Synta Pharmaceuticals Corp. Pyridine compounds
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
JP2007161585A (ja) * 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
WO2006001501A1 (fr) * 2004-06-25 2006-01-05 Taisho Pharmaceutical Co., Ltd. Dérivés de pyrrolopyrimidine et de pyrrolopyridine substitués avec de la tétrahydropyridine comme antagonistes du crf
DE102004032651A1 (de) * 2004-07-06 2006-02-16 Bayer Healthcare Ag Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
DE102004042607A1 (de) * 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
DE602005025924D1 (en) * 2004-09-20 2011-02-24 Xenon Pharmaceuticals Inc Royl-coa-desaturase
JP2008534453A (ja) * 2005-03-24 2008-08-28 バイエル・ヘルスケア・アクチェンゲゼルシャフト 再灌流傷害および再灌流障害の処置のための置換２−チオ−３，５−ジシアノ−４−フェニル−６−アミノピリジンの使用
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007073855A1 (fr) 2005-12-23 2007-07-05 Bayer Healthcare Ag Utilisation d’agonistes des recepteurs a1 de l’adenosine en vue de proteger les cellules renales contre les effets toxiques induits par des aminoglycosides au cours du traitement de maladies infectieuses
DE102006009813A1 (de) * 2006-03-01 2007-09-06 Bayer Healthcare Ag Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel
JP2009535307A (ja) * 2006-04-28 2009-10-01 アベキサ・リミテッド インテグラーゼ阻害剤３
WO2008008059A1 (fr) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Agents anti-cancer et leurs utilisations
DE102006042143A1 (de) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) * 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036075A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Ag Prodrugs und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008008838A1 (de) 2008-02-13 2009-08-20 Bayer Healthcare Ag Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung
DE102008013587A1 (de) * 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
WO2009143992A1 (fr) * 2008-05-29 2009-12-03 Bayer Schering Pharma Aktiengesellschaft Dicyanopyridines substituées par du 2-alcoxy et leur utilisation
DE102008062567A1 (de) * 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102008062566A1 (de) * 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
RS54378B1 (en) * 2009-05-01 2016-04-28 Inotek Pharmaceuticals Corporation PROCEDURE FOR REDUCING EYE PRESSURE IN PEOPLE

Also Published As

Publication number Publication date
PE20120430A1 (es) 2012-04-21
SG172968A1 (en) 2011-08-29
CN104844687A (zh) 2015-08-19
HK1168353A1 (en) 2012-12-28
JP2015120727A (ja) 2015-07-02
DOP2011000243A (es) 2017-10-15
CY1115403T1 (el) 2017-01-04
MA33000B1 (fr) 2012-01-02
HRP20140714T1 (hr) 2014-11-21
HK1211308A1 (en) 2016-05-20
HN2011002037A (es) 2013-12-02
KR101833188B1 (ko) 2018-02-27
EP2391620B1 (fr) 2014-05-07
LT2743270T (lt) 2017-02-27
SI2743270T1 (sl) 2017-03-31
BRPI1007308A2 (pt) 2016-02-10
UY32393A (es) 2010-08-31
EP2743270A1 (fr) 2014-06-18
TWI511968B (zh) 2015-12-11
KR20170029029A (ko) 2017-03-14
JP5908620B2 (ja) 2016-04-26
PE20150636A1 (es) 2015-05-08
MX2011007800A (es) 2011-11-18
US20100197609A1 (en) 2010-08-05
US8772498B2 (en) 2014-07-08
CU20110153A7 (es) 2012-02-15
EA019275B1 (ru) 2014-02-28
UA104613C2 (en) 2014-02-25
CA2750769A1 (fr) 2010-08-05
EP2391620A1 (fr) 2011-12-07
RS53448B (en) 2014-12-31
AR075050A1 (es) 2011-03-02
TW201504235A (zh) 2015-02-01
US8420825B2 (en) 2013-04-16
MY156434A (en) 2016-02-26
DK2391620T3 (da) 2014-08-11
ECSP11011235A (es) 2011-10-31
NZ594267A (en) 2013-09-27
JP5693469B2 (ja) 2015-04-01
GT201100205A (es) 2013-08-21
TWI457126B (zh) 2014-10-21
US20140296515A1 (en) 2014-10-02
HRP20170206T1 (hr) 2017-04-07
JP2012516290A (ja) 2012-07-19
US20130267700A1 (en) 2013-10-10
JO2927B1 (en) 2015-09-15
CU24037B1 (es) 2014-11-27
PL2743270T3 (pl) 2017-04-28
KR20110108377A (ko) 2011-10-05
KR101717305B1 (ko) 2017-03-16
AU2010207786A1 (en) 2011-08-25
PL2391620T3 (pl) 2014-09-30
CA2962039A1 (fr) 2010-08-05
EP2743270B1 (fr) 2016-12-21
AU2010207786B2 (en) 2015-10-22
ES2614702T3 (es) 2017-06-01
CA2750769C (fr) 2018-08-21
CY1118601T1 (el) 2017-07-12
DE102009006602A1 (de) 2010-08-05
CN102388040B (zh) 2015-05-13
TW201039821A (en) 2010-11-16
WO2010086101A1 (fr) 2010-08-05
ES2473966T3 (es) 2014-07-08
CR20110407A (es) 2012-01-02
PT2391620E (pt) 2014-06-25
IL214019A0 (en) 2011-08-31
PT2743270T (pt) 2017-02-15
CO6400193A2 (es) 2012-03-15
HUE032008T2 (en) 2017-08-28
CN102388040A (zh) 2012-03-21
EA201101111A1 (ru) 2012-02-28
DK2743270T3 (en) 2017-02-20
CN104844687B (zh) 2019-04-02
SI2391620T1 (sl) 2014-08-29

Similar Documents

Publication Publication Date Title
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
WO2012076466A3 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
TN2015000026A1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
IN2015KN00262A (fr)
IN2012DN02805A (fr)
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
EP2418945A4 (fr) Compositions de sel minéral/acide sulfonique et procédés d'utilisation
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
ZA201108305B (en) Novel p2x7r antagonists and their use
WO2010139979A3 (fr) Procédés d'élaboration de formes cristallines
TN2011000595A1 (en) Substituted piperidines
MY150931A (en) Substituted oxazolidinones and their use
IN2012DN00763A (fr)
MX339361B (es) Derivados de alternano.
TN2011000596A1 (en) Substituted piperidines
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
PT2247573E (pt) Sais carbónicos e de ácido sulfúrico de ésteres de 3-(2,2,2- trimetil-hidrazínio)propionato e sua utilização para a preparação de di-hidrato de 3-(2,2,2-trimetilhidrazínio) propionato
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
AU2016219657A1 (en) Stable pharmaceutical composition and methods of using same